



Nomenclature for kidney function and disease—executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference

Andrew S. Levey ^{1*}, Kai-Uwe Eckardt ^{2*}, Nijsje M. Dorman ³, Stacy L. Christiansen⁴, Michael Cheung ⁵, Michel Jadoul ⁶, and Wolfgang C. Winkelmayer ⁷

¹Division of Nephrology, Tufts Medical Center, Box 391, 800 Washington Street, Boston, MA 02111, USA; ²Department of Nephrology and Medical Intensive Care, Charité—Universitätsmedizin Berlin, Augustenburger Platz 1, Berlin 13353, Germany; ³AJKD, Philadelphia, PA 19104, USA; ⁴JAMA, Chicago, IL 60654, USA; ⁵KDIGO, Avenue Louise 65, Suite 11, Brussels 1050, Belgium; ⁶Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Avenue Hippocrate 10, Brussels 1200, Belgium; and ⁷Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA

Received 30 March 2020; revised 5 May 2020; editorial decision 24 July 2020; accepted 1 September 2020; online publish-ahead-of-print 3 November 2020

Abstract

The worldwide burden of kidney disease is rising, but public awareness remains limited, underscoring the need for more effective communication by stakeholders in the kidney health community. Despite this need for clarity, the nomenclature for describing kidney function and disease lacks uniformity. In June 2019, Kidney Disease: Improving Global Outcomes (KDIGO) convened a consensus conference with the goal of standardizing and refining the nomenclature used in the English language to describe kidney function and disease, and of developing a glossary that could be used by journals in scientific publications. Guiding principles of the conference were that the revised nomenclature should be patient-centred, precise, and consistent with nomenclature used in the KDIGO guidelines. Conference attendees reached general consensus on the following recommendations: (i) to use 'kidney' rather than 'renal' or 'nephro' when referring to kidney disease and kidney function; (ii) to use 'kidney failure' with appropriate descriptions of the presence or absence of symptoms, signs, and treatment rather than 'end-stage' kidney disease; (iii) to use the KDIGO definition and classification of acute kidney diseases and disorders (AKD) and acute kidney injury (AKI) rather than alternative descriptions to define and classify the severity of AKD and AKI; (iv) to use the KDIGO definition and classification of chronic kidney disease (CKD) rather than alternative descriptions to define and classify the severity of CKD; and (v) to use specific kidney measures, such as albuminuria or decreased glomerular filtration rate, rather than 'abnormal or reduced kidney function' to describe alterations in kidney structure and function. A proposed five-part glossary contains specific items for which there was general agreement. Conference attendees acknowledged limitations of the recommendations and glossary but considered that standardizing scientific nomenclature is essential for improving communication.

* Corresponding authors. Tel: 1-617-636-5898, Email: alevey@tuftsmedicalcenter.org (A.S.L.); Tel: +49 30 4505 14002, Email: kai-uwe.eckardt@charite.de (K.-U.E.)

This editorial is published concurrently in multiple journals with minor differences and serves as an executive summary of the full report published in *Kidney International*.¹ Excerpts are adapted with the permission of KDIGO and the International Society of Nephrology.


© KDIGO 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Graphical Abstract


Why uniform nomenclature on kidney function and disease?

- Reduces confusion and errors in clinical practice
- Promotes consistency in research design, execution, and communication
 - Raises public awareness
- Facilitates communication between healthcare provider and patient
- Takes into account patient preferences and his/her needs and values
- Minimizes language ambiguity and mobilizes self-management and advocacy



Key take-home messages

- 1 Use 'kidney' rather than 'renal' or 'nephro-' when referring to kidney disease and kidney function
- 2 Use 'kidney failure' with appropriate descriptions of presence or absence of symptoms, signs, and treatment rather than 'end-stage kidney disease' since latter term is not patient-sensitive and connotes stigma
- 3 Use the KDIGO definition and classification of acute kidney diseases and disorders (AKD) and acute kidney injury (AKI) rather than alternative descriptions to define and classify severity of AKD and AKI; AKI stages (1, 2, 3) should be used to denote severity of AKI
- 4 Use the KDIGO definition and classification of CKD rather than alternative descriptions to define and classify CKD. Ascertainment of CKD when GFR > 60 ml/min/1.73 m² requires assessment for markers of kidney damage (e.g., albuminuria). CKD should be classified according to cause and categories of GFR and albuminuria (CGA); severity of CKD should correspond to risk categories (i.e., KDIGO heatmap, right)
- 5 Use specific kidney measures such as albuminuria or decreased GFR to describe alterations in kidney structure and function, respectively, rather than general descriptors such as 'abnormal' or 'reduced' kidney function. Do not equate albuminuria or proteinuria as 'decreased kidney function' since they are markers of kidney damage



Keywords

Acute kidney diseases and disorders • Acute kidney injury • Chronic kidney disease • Kidney disease • Kidney failure • Kidney function • Kidney measures • Nomenclature • Patient-centredness • Precision medicine

A primary obligation of medical journals is the responsible, professional, and expeditious delivery of knowledge from researchers and practitioners to the wider community.² The task of journal editors, therefore, rests not merely in selecting what to publish, but in large measure judging how it might best be communicated. The challenge of improving the descriptions of kidney function and disease in medical publishing was the impetus for a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference held in June 2019. The conference goals included standardizing and refining kidney-related nomenclature used in English language scientific articles and developing a glossary that could be used by journals.³

While a glossary of kidney-related nomenclature is most applicable to kidney subspecialty journals, the interdependency of the kidney with other organ systems makes this glossary broadly relevant. For instance, accelerated atherosclerosis was quickly recognized as a complication in patients with kidney failure treated by maintenance haemodialysis,⁴ and guidelines have called attention to kidney disease as an independent risk factor for cardiovascular disease for >20 years.^{5–13} The Global Burden of Disease Study estimated the worldwide prevalence of chronic kidney disease (CKD) in 2017 to be ~697.5 million people (9.1% of the population), with 1.2 million

deaths due to kidney failure, and an additional 1.4 million deaths due to cardiovascular disease (4.6% of total mortality).¹⁴ An earlier report concluded that, in 2013, 'Compared with metabolic risk factors, reduced glomerular filtration rate (GFR) ranked below high systolic blood pressure, high body mass index, and high fasting plasma glucose, and similarly with high total cholesterol'.¹⁵

The rationale for the 2019 KDIGO conference was that the worldwide burden of kidney disease is rising, but public awareness remains limited, underscoring the need for effective communication by all stakeholders in the kidney health community.^{14,16–18} Despite this need, the nomenclature for describing kidney function and disease lacks uniformity and clarity. Two decades ago, a survey of hundreds of published articles and meeting abstracts reported a broad array of overlapping, confusing terms for CKD and advocated adoption of unambiguous terminology.¹⁹ Nevertheless, terms flagged by that analysis as problematic, such as 'chronic renal failure' and 'pre-dialysis', still appear in current-day publications. A coherent, shared nomenclature could improve communication at all levels, including not only to better appreciate the burden of disease but also to aid understanding about how patients feel about their disease, allow more effective communication between kidney disease specialists and other

Prognosis of CKD by GFR and albuminuria categories: KDIGO 2012				Persistent albuminuria categories		
				Description and range		
				A1	A2	A3
				Normal to mildly increased	Moderately increased	Severely increased
				< 30 mg/g < 3 mg/mmol	30–300 mg/g 3–30 mg/mmol	> 300 mg/g > 30 mg/mmol
GFR categories (ml/min/1.73 m ²) Description and range	G1	Normal or high	≥ 90			
	G2	Mildly decreased	60–89			
	G3a	Mildly to moderately decreased	45–59			
	G3b	Moderately to severely decreased	30–44			
	G4	Severely decreased	15–29			
	G5	Kidney failure	< 15			

Figure 1 Chronic kidney disease nomenclature used by Kidney Disease: Improving Global Outcomes. Chronic kidney disease is defined as abnormalities of kidney structure or function, present for >3 months, with implications for health. Chronic kidney disease is classified based on cause, glomerular filtration rate category (G1–G5), and albuminuria category (A1–A3), abbreviated as CGA. Prognosis of chronic kidney disease by glomerular filtration rate and albuminuria category is colour-coded as follows: green, low risk (if no other markers of kidney disease, no chronic kidney disease); yellow, moderately increased risk; orange, high risk; red, very high risk. CKD, chronic kidney disease; GFR, glomerular filtration rate; KDIGO, Kidney Disease: Improving Global Outcomes.

clinicians, advance more straightforward comparison and integration of datasets, enable better recognition of gaps in knowledge for future research, and facilitate more comprehensive public health policies for acute and CKDs.

Developing consistent, patient-centred, and precise descriptions of kidney function and disease in the scientific literature is an important objective to align communication in clinical practice, research, and public health. While some terms have been in use for decades, the increased exchange of information among stakeholders makes it timely to revisit nomenclature to ensure consistency. The goal is to facilitate communication within and across disciplines and between practitioners and patients, with the ultimate hope of improving outcomes through consistency and precision.

Attendees at the conference included editors of many kidney subspecialty journals, kidney subspecialty editors at high-impact general medical journals and a few journals from other subspecialties, experienced authors of clinical kidney health research, and patients. Guiding principles of the conference were that the revised nomenclature should be patient-centred, precise, and consistent with nomenclature used in the KDIGO guidelines. The discussion focused on the general description of acute and CKD and kidney measures, rather than specific kidney diseases and particular measures of function and structure. Classifications of causes of kidney disease and procedures, performance measures, and outcomes metrics for dialysis and transplantation were considered beyond the scope of discussion.

As described in detail in the conference report,¹ the meeting attendees reached general consensus on the following

recommendations for English language medical journals: (i) to use 'kidney' rather than 'renal' or 'nephro' when referring to kidney disease and kidney function; (ii) to use 'kidney failure' with appropriate descriptions of presence or absence of symptoms, signs, and treatment rather than 'end-stage kidney disease'; (iii) to use the KDIGO definition and classification of acute kidney diseases and disorders (AKD) and acute kidney injury (AKI) rather than alternative descriptions to define and classify the severity of AKD and AKI; (iv) to use the KDIGO definition and classification of CKD rather than alternative descriptions to define and classify CKD (Figure 1, Take home figure); and (v) to use specific kidney measures, such as albuminuria or decreased GFR, rather than 'abnormal' or 'reduced' kidney function to describe alterations in kidney structure and function (Table 1). Accordingly, the proposed glossary contains five corresponding sections and comprises specific items for which there was general agreement among the conference participants (<https://kdigo.org/conferences/nomenclature/>, Supplementary material online, Table S1).¹ For each section, the glossary includes preferred terms, abbreviations, descriptions, and terms to avoid, with the acknowledgment that journals may choose which of the recommendations to implement, and that journal style will dictate when and how to abbreviate terms to be consistent with nomenclature for other diseases.

A guiding principle for the development of the glossary was patient-centredness. The Health and Medicine Division of US National Academies of Sciences defines patient-centred care as '[p]roviding care that is respectful of, and responsive to, individual patient preferences, needs and values, and ensuring that patient values guide all clinical decisions'.²⁰ One of the 10 general principles recommended for redesign of the health system is that 'Knowledge is shared and information flows freely. Patients should have unfettered access to their own medical information and to clinical knowledge. Clinicians and patients should communicate effectively and share information'. In principle, the terms used to describe kidney function and disease should be understandable to all, with acknowledgment of variation in the level of health literacy. Use of multiple terms with similar meaning can lead to confusion, as can use of terms that forecast the future (such as 'pre-dialysis'), rather than describe the present. However, convergence of multiple names into an accepted set of terms does require that users of the glossary are willing to accept that labels that have been pre-eminent historically, and that may be more familiar or memorable even now, should now be superseded.²¹

Of equal importance to patient-centredness in the development of the glossary was precision, which can generally be defined as exactness or accuracy.²¹ How medicine is defined and understood is changing rapidly from a descriptive disease-based categorization in which multiple pathogenetic pathways may be conflated to mechanism-based categorization that will promote more precise management of clinical problems. The latter approach, in which a molecular profile is added to the clinical and morphologic profile, has already revolutionized diagnosis and treatment in oncology. In nephrology, the ongoing Kidney Precision Medicine Project, funded by the National Institutes of Health, seeks to ethically obtain and evaluate kidney biopsies from participants with AKI or CKD; create a kidney tissue atlas; define disease subgroups; and identify cells, pathways, and targets for novel therapies.²² As has occurred in oncology, it is anticipated that refinements that result in more precise disease descriptions will be incorporated into current nomenclature for


Table 1 Key takeaways from the conference

- Use the term 'kidney' rather than 'renal' to describe kidney function and kidney disease. In English the terms renal and kidney are still used interchangeably, resulting in different acronyms describing the same condition or status (e.g. ESRD/ESKD and RRT/KRT). It is more likely that patients and the public would understand the terms incorporating the more familiar noun 'kidney', rather than the less familiar adjective 'renal', which is derived from Latin and is labelled as technical in some dictionaries. Although writing guides may generally favour an appropriate adjective over a noun as a modifier, there are high-profile precedents for the use of 'kidney' as a modifier, such as AKI, CKD, and NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases)
- Avoid the term 'end-stage'. Although rooted in US law, the term is not patient sensitive, may connote a stigma, and may discourage advocacy. In the USA, ESRD (or ESKD) is a synonym for receipt of KRT. However, KRT is a treatment rather than a disease. The term 'kidney failure', which is defined as $\text{GFR} < 15 \text{ mL/min/1.73 m}^2$ or treatment by dialysis, is as comprehensive as 'ESRD/ESKD', without suffering from its limitations
- Improve characterization of the full spectrum of kidney failure. Although all patients with kidney failure have $\text{GFR} < 15 \text{ mL/min/1.73 m}^2$ or are undergoing treatment by dialysis, the severity of symptoms varies greatly. We lack terms to describe the severity of symptoms and signs, and yet they are indications for initiating KRT. There are also no common patient-reported outcome measures to describe severity. The term 'kidney failure' in a chronic setting is defined as > 3 months, whereas in an acute setting (i.e. AKI Stage 3), it is reserved for a duration ≤ 3 months. Kidney failure could be further classified according to patient-reported outcomes (symptoms)
- Use more-descriptive terms for treatments for kidney failure. Many patients with kidney failure do not undergo KRT. The terms 'treated' vs. 'untreated' have been used, but this is not consistent with the idea that supportive care is indeed treatment. Furthermore, in some cases, patients choose supportive care rather than KRT; in other cases, they do not have a choice because of lack of insurance or lack of availability. Finally, some patients may not be under the care of a physician at all
- Avoid the use of 'CKD' as a synonym for ' $\text{GFR} < 60 \text{ mL/min/1.73 m}^2$ '. CKD includes markers of kidney damage or $\text{GFR} < 60 \text{ mL/min/1.73 m}^2$ for > 3 months, so ascertainment of GFR without assessment for markers of kidney damage is insufficient for classification of CKD status when $\text{GFR} > 60 \text{ mL/min/1.73 m}^2$. If chronicity is not documented, it can be inferred on the basis of corroborative clinical data or presumed in the absence of clinical data to the contrary
- Avoid the use of using 'AKI' as a synonym for 'AKD'. AKD refers to kidney diseases and disorders with duration of ≤ 3 months, whereas AKI refers to kidney diseases and disorders with onset within 1 week
- Use 'CKD GFR and albuminuria categories' and 'AKI stages' to describe disease severity rather than employing ill-defined terms such as 'mild', 'moderate', 'severe', and 'advanced'
- Use the terms 'GFR categories' and 'albuminuria categories' rather than 'CKD stages' when describing the level of GFR and albuminuria in populations without CKD or without ascertainment of both GFR and albuminuria
- Use the term 'risk categories' to describe combinations of G (GFR) and A (albuminuria) categories from the KDIGO heat map (Figure 1)
- Use specific terms, such as 'GFR', 'tubular secretion', 'tubular reabsorption', 'albuminuria', and 'proteinuria', rather than general terms, such as 'abnormal' or 'reduced' kidney function, damage or injury, when possible. Because kidney function comprises several functional categories, including excretory, endocrine, and metabolic functions, it should be described as specifically as possible. GFR is closely linked with the excretory function but should not be used as a synonym, because tubular reabsorption and excretion also contribute to excretory function
- When referring to 'decreased or decreasing GFR', avoid the use of different, poorly defined terms such as: 'impaired kidney function', 'renal insufficiency', 'renal dysfunction', 'renal impairment', 'worsening kidney function', and 'kidney function decline'
- When referring to GFR, use descriptive abbreviations (mGFR for measured GFR and eGFR for estimated GFR), with specific notation based on the endogenous filtration markers used (e.g. eGFR_{Cr} , eGFR_{Cys} , and $\text{eGFR}_{\text{Cr-Cys}}$). Additional detail can be given in the methods. For mGFR, the methods should describe the exogenous filtration marker (e.g. inulin, iothalamate, iohexol) and clearance method (urinary clearance, plasma clearance). For eGFR, the methods should describe the estimating equation used (CKD-EPI; MDRD study)
- Avoid referring to 'albuminuria' or 'proteinuria' as 'decreased kidney function'. Albuminuria and proteinuria are markers of kidney damage, rather than measures of kidney function
- When referring to albuminuria or proteinuria, avoid the terms 'microalbuminuria' and 'macroalbuminuria/clinical proteinuria'. Use the terms 'moderately increased' or 'severely increased' instead
- When referring to albuminuria and proteinuria, use descriptive abbreviations, such as 'urine albumin or protein excretion rates (AER and PER)' and 'urine albumin-creatinine or protein-creatinine ratios (ACR and PCR)'

ACR, albumin-creatinine ratio; AER, albumin excretion rate; AKD, acute kidney diseases and disorders; AKI, acute kidney injury; CKD, chronic kidney disease; CKD-EPI, CKD Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; eGFR_{Cr} , estimated glomerular filtration rate derived from creatinine; $\text{eGFR}_{\text{Cr-Cys}}$, estimated glomerular filtration rate derived from creatinine and cystatin C; eGFR_{Cys} , estimated glomerular filtration rate derived from cystatin C; ESKD, end-stage kidney disease; ESRD, end-stage renal disease; GFR, glomerular filtration rate; KDIGO, Kidney Disease: Improving Global Outcomes; KRT, kidney replacement therapy; MDRD, Modification of Diet in Renal Disease; mGFR, measured glomerular filtration rate; NIDDK, National Institute of Diabetes and Digestive and Kidney Diseases; PCR, protein-creatinine ratio; PER, protein excretion rate; RRT, renal replacement therapy; US, United States.

Why uniform nomenclature on kidney function and disease?

- Reduces confusion and errors in clinical practice
- Promotes consistency in research design, execution, and communication
 - Raises public awareness
- Facilitates communication between healthcare provider and patient
- Takes into account patient preferences and his/her needs and values
- Minimizes language ambiguity and mobilizes self-management and advocacy



- Key take-home messages**
- 1 Use 'kidney' rather than 'renal' or 'nephro-' when referring to kidney disease and kidney function
 - 2 Use 'kidney failure' with appropriate descriptions of presence or absence of symptoms, signs, and treatment rather than 'end-stage kidney disease' since latter term is not patient-sensitive and connotes stigma
 - 3 Use the KDIGO definition and classification of acute kidney diseases and disorders (AKD) and acute kidney injury (AKI) rather than alternative descriptions to define and classify severity of AKD and AKI; AKI stages (1, 2, 3) should be used to denote severity of AKI
 - 4 Use the KDIGO definition and classification of CKD rather than alternative descriptions to define and classify CKD. Ascertainment of CKD when GFR > 60 ml/min/1.73 m² requires assessment for markers of kidney damage (e.g., albuminuria). CKD should be classified according to cause and categories of GFR and albuminuria (CGA); severity of CKD should correspond to risk categories (i.e., KDIGO heatmap, right)
 - 5 Use specific kidney measures such as albuminuria or decreased GFR to describe alterations in kidney structure and function, respectively, rather than general descriptors such as 'abnormal' or 'reduced' kidney function. Do not equate albuminuria or proteinuria as 'decreased kidney function' since they are markers of kidney damage

Prognosis of CKD by GFR and albuminuria categories: KDIGO 2012

			Persistent albuminuria categories			
			Description and range			
			A1	A2	A3	
			Normal to mildly increased	Moderately increased	Severely increased	
			< 30 mg/g < 3 mg/mmol	30–300 mg/g 3–30 mg/mmol	> 300 mg/g > 30 mg/mmol	
GFR categories (ml/min/1.73 m ²) Description and range	G1	Normal or high	≥ 90			
	G2	Mildly decreased	60–89			
	G3a	Mildly to moderately decreased	45–59			
	G3b	Moderately to severely decreased	30–44			
	G4	Severely decreased	15–29			
	G5	Kidney failure	< 15			

- low risk (if no other markers of kidney disease, no CKD)
- moderately increased risk
- high risk
- very high risk

Take home figure Objectives and conclusions of the KDIGO consensus conference on nomenclature for kidney function and disease.

kidney function and disease, rather than replace it altogether. Thus, although the glossary is designed to be consistent with current knowledge and stable enough to remain relevant for the foreseeable future, it is also intended to be sufficiently flexible to accommodate new vocabulary arising with advances in the field.

A central strength of the proposed glossary is that it is based on existing KDIGO definitions, classifications, and nomenclature for acute and CKD. In addition, it was developed using a systematic process, including articulation of a clear and transparent rationale (patient-centredness and precision); capture of stakeholder viewpoints via patient focus groups and a corresponding survey; a period of public comment on conference scope; and attainment of consensus among attendees at the conference. While the recommendations are not likely to answer all concerns, the consensus among conference attendees was that standardizing scientific nomenclature is a necessary first step to improving communications among clinicians, researchers, and public health officials, and with patients, their families and caregivers, and the public.

Limitations of the proposed glossary are that it is restricted to English (nuances may be difficult to translate); only a limited number of stakeholders could participate due to practical reasons; it is not comprehensive (it does not include disease classification, dialysis, transplantation); and further specification will be required for studies in children. For these and other reasons, we consider the current recommendations for a glossary as an important starting point, and it will require future expansion and updating.

Achieving consensus among conference attendees and publication of the conference report and glossary is only the first step in

implementation of a revised nomenclature. The glossary will be freely available on the KDIGO website (<https://kdigo.org/conferences/nomenclature/>) and [Supplementary material online, Table S1](#). Elements of the glossary will be included in online updates to the newly released (11th) edition of the *AMA Manual of Style*.²³ Medical journals adopting the recommendations will need to determine how to implement them and this process will require education of editorial staff as well as proactive communication with authors, generally and with regard to specific manuscripts. Translations to languages other than English will be necessary for the selection of preferred terms. If successful, further implementation in clinical practice, research, and public health will require more widespread dissemination and professional education and integration into electronic health records. Introduction of new terms will require revisions to definitions of exposures, outcomes, and adjustment variables in research studies and to revisions to search strategies of bibliographic medical databases. Improving communication with patients and the public will require efforts to improve patient education and health literacy for the public and guides to communication with patients that provide appropriate translation to people with varying health literacy. Professional societies, industry, and patient advocacy organizations will be critical to these efforts.

Advances in research, particularly in precision medicine, will introduce a myriad of new terms and novel concepts requiring incorporation into disease definitions and classifications. In addition, the increasing prominence and participation of patient and caregiver communities in defining research objectives and best practices in clinical care objectives will further elucidate the

characteristics of patient-centred terminology. Expanding and updating the KDIGO glossary can be accomplished as part of the activities of future KDIGO guideline workgroups and future conferences.

Supplementary material

Supplementary material is available at *European Heart Journal* online.

Acknowledgements

The authors are grateful to Juhi Chaudhari, MPH, at Tufts Medical Center, Boston, MA, USA, for assistance with manuscript preparation. The conference was sponsored by KDIGO and was in part supported by unrestricted educational grants from AstraZeneca, Bayer HealthCare, Boehringer Ingelheim, Fresenius Medical Care, Roche, and Sanofi. The content of this article does not necessarily reflect the views or opinions of the organizations or journals that were represented at the conference. Responsibility for the information and views expressed is limited to the co-authors.

Conflict of interest: A.S.L. declared having received research support from AstraZeneca, National Institute of Diabetes and Digestive and Kidney Diseases, and National Kidney Foundation. K.-U.E. declared having received consultancy fees from Akebia, Bayer, and Genzyme; speaker honoraria from Bayer and Vifor; and research support from Amgen, AstraZeneca, Bayer, Fresenius Medical Care, and Genzyme. N.M.D. declared having equity ownership/stock options from Eli Lilly & Co. M.J. and declared having received consultancy fees from Astellas, AstraZeneca, GlaxoSmithKline, MSD, and Vifor Fresenius Medical Care Renal Pharma; speaker honoraria from Abbvie, Amgen, Menarini, MSD, and Vifor Fresenius Medical Care Renal Pharma; travel support from Amgen; and research support from Alexion, Amgen, Janssen-Cilag, Otsuka, and Roche. W.C.W. declared having received consultancy fees from Akebia, AMAG, Amgen, AstraZeneca, Bayer, Daiichi-Sankyo, Relypsa, and ZS Pharma; speaker honoraria from FibroGen; and research support from National Institutes of Health. All other authors declared no conflict of interest.

References

- Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, Inker LA, Levin A, Mehrotra R, Palevsky PM, Perazella MA, Tong A, Allison SJ, Bockenhauer D, Briggs JP, Bromberg JS, Davenport A, Feldman HI, Fouque D, Gansevoort RT, Gill JS, Greene EL, Hemmelgarn BR, Kretzler M, Lambie M, Lane PH, Laycock J, Leventhal SE, Mittelman M, Morrissey P, Ostermann M, Rees L, Ronco P, Schaefer F, St Clair Russell J, Vinck C, Walsh SB, Weiner DE, Cheung M, Jadoul M, Winkelmayer WC. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. *Kidney Int* 2020;**97**:1117–1129.
- Levey AS, Weiner DE. Staying put, but not standing still. *Am J Kidney Dis* 2012;**59**:1–3.
- Kidney Disease: Improving Global Outcomes. Consensus Conference on Nomenclature for Kidney Function & Disease. 2019. <https://kdigo.org/conferences/nomenclature/> (27 May 2020).
- Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. *N Engl J Med* 1974;**290**:697–701.
- Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen M-R, Tokgozoglul, Wiklund O; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J* 2020;**41**:111–188.
- Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasike BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease. *Circulation* 2003;**108**:2154–2169.
- Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasike BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT Jr. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. *Am J Kidney Dis* 1998;**32**:853–906.
- Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruijlope LM, Ruschitzka F, Rutten FH, van der Meer PJ. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016;**37**:2129–2200.
- Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener H-C, Heidbuchel H, Hendricks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, DeFtereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GYH, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J* 2016;**37**:2893–2962.
- Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet J-P, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferović PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 2019;**40**:87–165.
- Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruijlope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J* 2018;**39**:3021–3104.
- Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsson T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J* 2020;**41**:407–477.
- Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Juni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC; ESC Scientific Document Group. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J* 2020;**41**:255–323.
- GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2020;**395**:709–733.
- Thomas B, Matsushita K, Abate KH, Al-Aly Z, Arnlov J, Asayama K, Atkins R, Badawi A, Ballew SH, Banerjee A, Barreger L, Barrett-Connor E, Basu S, Bello AK, Bensenor I, Bergstrom J, Bikbov B, Blosser C, Brenner H, Carrero JJ, Chadban S, Cirillo M, Cortinovis M, Courville K, Dandona L, Dandona R, Estep K, Fernandes J, Fischer F, Fox C, Gansevoort RT, Gona PN, Gutierrez OM, Hamidi S, Hanson SW, Himmelfarb J, Jassal SK, Jee SH, Jha V, Jimenez-Corona A, Jonas JB, Kengne AP, Khader Y, Khang YH, Kim YJ, Klein B, Klein R, Kokubo Y, Kolte D, Lee K, Levey AS, Li Y, Lotufo P, El Razek HMA, Mendoza W, Metoki H, Mok Y, Muraki I, Muntner PM, Noda H, Ohkubo T, Ortiz A, Perico N, Polkinghorne K, Al-Radaddi R, Remuzzi G, Roth G, Rothenbacher D, Satoh M, Saum KU, Sawhney M, Schottker B, Shankar A, Shlipak M, Silva DAS, Toyoshima H, Ukwaja K, Umesawa M, Vollset SE, Warnock DG, Werdecker A, Yamagishi K, Yano Y, Yonemoto N, Zaki MES, Naghavi M, Forouzanfar MH, Murray CJL, Coresh J, Vos T; on behalf of the Global Burden of Disease 2013 GFR Collaborators. Global cardiovascular and renal outcomes of reduced GFR. *J Am Soc Nephrol* 2017;**28**:2167–2179.
- Saran R, Robinson B, Abbott KC, Agodoa LYC, Bhavane N, Bragg-Gresham J, Balkrishnan R, Dietrich X, Eckard A, Eggers PW, Gaipov A, Gillen D, Gipson D, Hailpern SM, Hall YN, Han Y, He K, Herman W, Heung M, Hirth RA, Hutton D,

- Jacobsen SJ, Jin Y, Kalantar-Zadeh K, Kapke A, Kovesdy CP, Lavalley D, Leslie J, McCullough K, Modi Z, Molnar MZ, Montez-Rath M, Moradi H, Morgenstern H, Mukhopadhyay P, Nallamothu B, Nguyen DV, Norris KC, O'Hare AM, Obi Y, Park C, Pearson J, Pisoni R, Potukuchi PK, Rao P, Repeck K, Rhee CM, Schragger J, Schaubel DE, Selewski DT, Shaw SF, Shi JM, Shieu M, Sim JJ, Soohoo M, Steffick D, Streja E, Sumida K, Tamura MK, Tilea A, Tong L, Wang D, Wang M, Woodside KJ, Xin X, Yin M, You AS, Zhou H, Shahinian V. US renal data system 2017 annual data report: epidemiology of kidney disease in the United States. *Am J Kidney Dis*. 2018;**71**(3 Suppl 1):S1–S676.
17. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;**392**:1789–1858.
18. Plantinga LC, Boulware LE, Coresh J, Stevens LA, Miller ER, Saran R, Messer KL, Levey AS, Powe NR. Patient awareness of chronic kidney disease: trends and predictors. *Arch Intern Med* 2008;**168**:2268–2275.
19. Hsu CY, Chertow GM. Chronic renal confusion: insufficiency, failure, dysfunction, or disease. *Am J Kidney Dis* 2000;**36**:415–418.
20. Committee on the Quality of Healthcare in the United States. *Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century*. Washington, DC: National Academy Press; 2001.
21. *Oxford Dictionary of English*. 3rd ed. Oxford, UK: Oxford University Press; 2010.
22. Kidney Precision Medicine Project. <https://kpmp.org/> (3 May 2020).
23. Christiansen S, Iverson C, Flanagan A. *American Medical Association. AMA Manual of Style: A Guide for Authors and Editors*. 11th ed. New York, USA: Oxford University Press; 2020.